Retatrutide
LY3437943, LY-3437943
A synthetic peptide acting as a triple agonist for GLP-1, GIP, and glucagon receptors, designed for treating obesity and type 2 diabetes by promoting weight loss and glycemic control.
Active Not Recruiting
PHASE3
NCT05929079
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05959096
A Study of LY3437943 in Healthy Participants With a High Body Mass Index
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT05882045
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05611957
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06039826
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT06383390
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT04823208
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT04143802
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE1
NCT06982846
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06297603
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT03841630
A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT07035093
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025